` NSPR (InspireMD Inc) vs S&P 500 Comparison - Alpha Spread

NSPR
vs
S&P 500

Over the past 12 months, NSPR has underperformed S&P 500, delivering a return of -5% compared to the S&P 500's 24% growth.

Stocks Performance
NSPR vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NSPR vs S&P 500

Loading
NSPR
S&P 500
Difference

Performance By Year
NSPR vs S&P 500

Loading
NSPR
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
InspireMD Inc vs Peers

S&P 500
NSPR
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

InspireMD Inc
Glance View

Market Cap
71.2m USD
Industry
Health Care

InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

NSPR Intrinsic Value
2.73 USD
Overvaluation 1%
Intrinsic Value
Price
Back to Top